ERBB2 and breast carcinoma: Therefore, we recommend that apart from hormone receptors and HER2/neu, Ki67 should be evaluated in all breast cancers undergoing neoadjuvant chemotherapy to stratify patients who can benefit more from neoadjuvant chemotherapy.